Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia Journal Article
| Authors: | Cole, P. D.; Kim, S. Y.; Li, Y.; Schembri, A.; Kelly, K. M.; Sulis, M. L.; Vrooman, L.; Welch, J. J. G.; Ramjan, S.; Silverman, L. B.; Sands, S. A. |
| Article Title: | Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia |
| Abstract: | Purpose: Neurocognitive impairment is frequently observed among survivors of childhood acute lymphoblastic leukemia (ALL) within the domains of attention, working memory, processing speed, executive functioning, and learning and memory. However, few studies have characterized the trajectory of treatment-induced changes in neurocognitive function beginning in the first months of treatment, to test whether early changes predict impairment among survivors. If correct, we hypothesize that those children who are most susceptible to early impairment would be ideal subjects for clinical trials testing interventions designed to protect against treatment-related neurocognitive decline. Methods: In this pilot study, we prospectively assessed neurocognitive functioning (attention, working memory, executive function, visual learning, and processing speed), using the Cogstate computerized battery at six time points during the 2 years of chemotherapy treatment and 1-year post-treatment (Dana-Farber Cancer Institute ALL Consortium protocol 11–001; NCT01574274). Results: Forty-three patients with ALL consented to serial neurocognitive testing. Of the 31 participants who remained on study through the final time point, 1 year after completion of chemotherapy, 28 (90%) completed at least five of six planned Cogstate testing time points. Performance and completion checks indicated a high tolerability (≥ 88%) for all subtests. One year after completion of treatment, 10 of 29 patients (34%) exhibited neurocognitive function more than 2 standard deviations below age-matched norms on one or more Cogstate subtests. Conclusions: Serial collection of neurocognitive data (within a month of diagnosis with ALL, during therapy, and 1-year post-treatment) is feasible and can be informative for evaluating treatment-related neurocognitive impairment. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| Keywords: | adolescent; adult; cancer chemotherapy; child; clinical article; leukemia; cancer patient; methotrexate; neurotoxicity; follow up; prospective study; biomarkers; acute lymphoblastic leukemia; late effects; population research; feasibility study; cerebrospinal fluid; pilot study; feasibility studies; pilot projects; neuropsychological test; neuropsychological tests; cognitive defect; attention; childhood leukemia; longitudinal study; learning; working memory; memory, short-term; short term memory; executive function; humans; human; male; female; article; neurologic disease assessment; neurocognitive; processing speed; cogstate |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 31 |
| Issue: | 2 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2023-02-01 |
| Start Page: | 109 |
| Language: | English |
| DOI: | 10.1007/s00520-022-07566-6 |
| PUBMED: | 36625831 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- MSK corresponding author is Stephen A. Sands -- Export Date: 1 February 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work